AZD4045, Daratumumab, AldesleukinA Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

Sponsor:

AstraZeneca

Code:

NCT07681596

Conditions

Relapsed or Refractory Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

AZD4045

Daratumumab

Aldesleukin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-01. This information was provided to ClinicalTrials.gov by AstraZeneca on 2026-08-27.